{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:05:43Z","timestamp":1648879543968},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1007\/s00120-007-1349-y","type":"journal-article","created":{"date-parts":[[2007,4,23]],"date-time":"2007-04-23T10:25:55Z","timestamp":1177323955000},"page":"651-655","source":"Crossref","is-referenced-by-count":0,"title":["Pr\u00e4vention der Osteoporose \u2013 wichtig f\u00fcr den Urologen?"],"prefix":"10.1007","volume":"46","author":[{"given":"G.","family":"L\u00fcmmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"R\u00fcbben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1349_CR1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1023\/A:1008923802001","volume":"11","author":"Ahonen","year":"2000","unstructured":"Ahonen MH, Tenkanen L, Teppo L et al. (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847\u2013852","journal-title":"Cancer Causes Control"},{"key":"1349_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000090956","volume":"52","author":"Allain","year":"2006","unstructured":"Allain TJ (2006) Prostate cancer, osteoporosis and fracture risk. Gerontology 52: 107\u2013110","journal-title":"Gerontology"},{"key":"1349_CR3","first-page":"4","volume":"167","author":"Australian","year":"1997","unstructured":"Australian National Consensus Conference (1997) The prevention and management of osteoporosis \u2013 consensus statement. Med J Aust 167(Suppl 1): 4\u201314","journal-title":"Med J Aust"},{"key":"1349_CR4","first-page":"3431","volume":"84","author":"Bilezikian","year":"1999","unstructured":"Bilezikian JP (1999) Osteoporosis in men. J Clin Endocrinol Metab 84: 3431\u20133434","journal-title":"J Clin Endocrinol Metab"},{"key":"1349_CR5","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC et al. (2000) Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"1349_CR6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00120-005-0906-5","volume":"44","author":"Diemer","year":"2005","unstructured":"Diemer T, Hauck EW, Rohde V, Weidner W (2005) Therapie des \u201eAging male\u201c. Urologe 44: 1173\u20131178","journal-title":"Urologe"},{"key":"1349_CR7","doi-asserted-by":"crossref","unstructured":"Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 18; 282: 637\u2013645","DOI":"10.1001\/jama.282.7.637"},{"key":"1349_CR8","first-page":"176","volume":"184","author":"Holmes-Walker","year":"2006","unstructured":"Holmes-Walker DJ, Woo H, Gurney H et al. (2006) Maintaining bone health in patients with prostate cancer. Med J Am 184: 176\u2013179","journal-title":"Med J Am"},{"key":"1349_CR9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00108-005-1417-6","volume":"46","author":"Jacob","year":"2005","unstructured":"Jacob F (2005) Prim\u00e4re und sekund\u00e4re Osteoporose. Internist 46(Suppl 1): 24\u201330","journal-title":"Internist"},{"key":"1349_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2005-837390","volume":"130","author":"Kann","year":"2005","unstructured":"Kann PH (2005) Sekund\u00e4re Osteoporose bei endokrinen Erkrankungen. Dtsch Med Wochenschr 130: 165\u2013170","journal-title":"Dtsch Med Wochenschr"},{"key":"1349_CR11","doi-asserted-by":"crossref","unstructured":"Kiebzak GM, Beinart GA, Perser K et al. (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 28; 162: 2217\u20132222","DOI":"10.1001\/archinte.162.19.2217"},{"key":"1349_CR12","first-page":"3069","volume":"85","author":"Kurland","year":"2000","unstructured":"Kurland ES, Cosman F, McMahon DJ et al. (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069\u20133076","journal-title":"J Clin Endocrinol Metab"},{"key":"1349_CR13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0022-5347(05)65095-1","volume":"167","author":"Matsumoto","year":"2002","unstructured":"Matsumoto AM, Tenover L, McClung M et al. (2002) The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol 167: 2105\u20132108","journal-title":"J Urol"},{"key":"1349_CR14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"10","author":"Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 10(344): 1434\u20131441","journal-title":"N Engl J Med"},{"key":"1349_CR15","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1097\/01.ju.0000061024.75334.40","volume":"169","author":"Ockrim","year":"2003","unstructured":"Ockrim JL, Lalani EN, Laniado ME et al. (2003) Transdermal estradiol therapy for advanced prostate cancer \u2013 forward to the past? J Urol 169: 1735\u20131737","journal-title":"J Urol"},{"key":"1349_CR16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"31","author":"Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 31(343): 604\u2013610","journal-title":"N Engl J Med"},{"key":"1349_CR17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"Maerevoet","year":"2005","unstructured":"Maerevoet M, Martin C, Duck L (2005) Osteonecrosis of the jaw and bisphosphonate. N Eng J Med 353: 99\u2013102","journal-title":"N Eng J Med"},{"key":"1349_CR18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1210\/er.2001-8002","volume":"23","author":"Papadimitropoulos","year":"2002","unstructured":"Papadimitropoulos E, Wells G, Shea B et al. (2002) Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23: 560\u2013569","journal-title":"Endocr Rev"},{"key":"1349_CR19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"28","author":"Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 28(346): 653\u2013661","journal-title":"N Engl J Med"},{"key":"1349_CR20","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0022-5347(05)65060-4","volume":"167","author":"Ross","year":"2002","unstructured":"Ross RW, Small EJ (2002) Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167: 1952\u20131956","journal-title":"J Urol"},{"key":"1349_CR21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(01)69080-3","volume":"167","author":"Scherr","year":"2002","unstructured":"Scherr D, Pitts WR Jr, Vaughn ED Jr (2002) Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167: 535\u2013538","journal-title":"J Urol"},{"key":"1349_CR22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(02)08706-8","volume":"25","author":"Seeman","year":"2002","unstructured":"Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 25(359): 1841\u20131850","journal-title":"Lancet"},{"key":"1349_CR23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2003.09.534","volume":"21","author":"Segal","year":"2003","unstructured":"Segal RJ, Reid RD, Courneya KS et al. (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21: 1653\u20131659","journal-title":"J Clin Oncol"},{"key":"1349_CR24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"13","author":"Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 13(352): 154\u2013164","journal-title":"N Engl J Med"},{"key":"1349_CR25","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","volume":"171","author":"Sieber","year":"2004","unstructured":"Sieber PR, Keiller DL, Kahnoski RJ et al. (2004) Bicalutamide 150\u00a0mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171: 2272\u20132276","journal-title":"J Urol"},{"key":"1349_CR26","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1158\/1078-0432.CCR-06-0846","volume":"15","author":"Smith","year":"2006","unstructured":"Smith MR (2006) Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 15(12): 6315\u20136319","journal-title":"Clin Cancer Res"},{"key":"1349_CR27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"27","author":"Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL et al. (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 27(345): 948\u201355","journal-title":"N Engl J Med"},{"key":"1349_CR28","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008\u20132012","journal-title":"J Urol"},{"key":"1349_CR29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"1349_CR30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Writing","year":"2002","unstructured":"Writing Group for the Women\u2018s Health Initiative Investigation (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2018s Health Initiative and randomised controlled trial. JAMA 288: 321\u2013333","journal-title":"JAMA"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1349-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-007-1349-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-007-1349-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T10:58:44Z","timestamp":1558609124000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-007-1349-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s00120-007-1349-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}